The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.

doi:10.1016/S0014-2999(02)01532-7

Paper

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.

Published Apr 26, 2002 · S. Jordan, V. Koprivica, Ruoyan Chen

European journal of pharmacology

Q1 SJR score

453

Citations

7

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Highly Cited

Study Snapshot

Aripiprazole, a novel antipsychotic, is a potent partial agonist at the human 5-HT1A receptor, potentially contributing to its efficacy against schizophrenia symptoms and favorable side-effect profile.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.

Sign up to use Study Snapshot

References

Citations